CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (54,054)	$ (63,078)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	1,968	704
Amortization (accretion) on marketable securities	0	(182)
Non-cash interest expense	116	116
Non-cash lease expense	856	538
Non-cash income from collaborative arrangements, net	(2,157)	(696)
Stock-based compensation expense	7,427	9,217
Impairment of advance for COVAXIN supply	0	4,074
Loss on disposal of fixed assets related to COVAXIN	0	363
Other	37	46
Changes in assets and liabilities:
Prepaid expenses and other current assets	361	(296)
Accounts payable and accrued expenses	4,137	(12,343)
Lease obligations	(833)	(517)
Net cash used in operating activities	(42,142)	(62,054)
Cash flows from investing activities
Purchases of marketable securities	0	(3,947)
Proceeds from the maturities of marketable securities	0	17,500
Purchases of property and equipment	(3,385)	(10,476)
Repayment of note receivable	0	0
Net cash (used in) provided by investing activities	(3,385)	3,077
Cash flows from financing activities
Proceeds (payments) from issuance of common stock, net	38,556	20,804
Payment of equity issuance costs	(2,889)	(355)
Proceeds from issuance of debt	30,000	500
Payments of debt issuance costs	(809)	(68)
Net cash provided by financing activities	64,858	20,881
Effect of changes in exchange rate on cash and restricted cash	28	(5)
Net (decrease) in cash and restricted cash	19,359	(38,101)
Cash and restricted cash at beginning of period	39,462	77,563
Cash and restricted cash at end of period	58,821	39,462
Supplemental disclosure of non-cash investing and financing transactions:
Purchase of property and equipment	0	2,189
Right-of-use assets related to operating leases	103	572
Series B Convertible Preferred Stock reacquisition	(1)	0
Issuance of common stock for Avenue Capital agreement	$ 1,000	$ 0